Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067951) CD1D AND TCR-NKT CELLS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067951 International Application No.: PCT/US2018/053506
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
C12N 5/0783 (2010.01) ,C07K 14/705 (2006.01) ,A61K 35/17 (2015.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
NANTCELL, INC. [US/US]; 9920 Jefferson Boulevard Culver City, California 60232, US
Inventors:
SOON-SHIONG, Patrick; US
NIAZI, Kayvan; US
Agent:
SHIN, Minyoung; US
Priority Data:
62/565,77629.09.2017US
62/585,49813.11.2017US
Title (EN) CD1D AND TCR-NKT CELLS
(FR) CELLULES CD1D ET TCR-NKT
Abstract:
(EN) Compositions, methods and uses of genetically modified NKT cells to induce an NKT cell immune response against tumor or to change a microenvironment of the tumor by suppressing an activity of myeloid-derived suppressor cells are presented. In some embodiments, naive NKT cells are obtained from a patient having a tumor, and are genetically engineered to include a chimeric protein, a T cell receptor, a hybrid T cell receptor replacing the endogenous T cell receptor, or one of CD40L and Fas-L. The naive or genetically modified NKT cells can be administered to a cancer patient to trigger and/or boost immune response against the tumor.
(FR) L'invention concerne des compositions, des procédés et des utilisations de cellules NKT génétiquement modifiées pour induire une réponse immunitaire en cellules NKT contre une tumeur ou pour modifier un micro-environnement de la tumeur par suppression d'une activité des cellules suppressives d'origine myéloïde. Dans certains modes de réalisation, des cellules NKT naïves sont obtenues à partir d'un patient ayant une tumeur, et sont génétiquement modifiées pour inclure une protéine chimérique, un récepteur de lymphocyte T, un récepteur de lymphocyte T hybride à la place du récepteur de lymphocyte T endogène, ou un du CD40L et Fas-L. Les cellules NKT naïves ou génétiquement modifiées peuvent être administrées à un patient atteint de cancer pour susciter et/ou amplifier une réponse immunitaire contre la tumeur.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)